Literature DB >> 14568974

An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems.

Peggy P Ho1, Paulo Fontoura, Pedro J Ruiz, Lawrence Steinman, Hideki Garren.   

Abstract

Bacterial DNA and immunostimulatory CpG oligodeoxynucleotides (ODNs) activate the innate immune system to produce proinflammatory cytokines. Shown to be potent Th1-like adjuvants, stimulatory CpG motifs are currently used as effective therapeutic vaccines for various animal models of infectious diseases, tumors, allergies, and autoimmune diseases. In this study, we show that the application of an immunomodulatory GpG ODN, with a single base switch from CpG to GpG, can effectively inhibit the activation of Th1 T cells associated with autoimmune disease. Moreover, this immunomodulatory GpG ODN suppresses the severity of experimental autoimmune encephalomyelitis in mice, a prototypic Th1-mediated animal disease model for multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568974     DOI: 10.4049/jimmunol.171.9.4920

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates.

Authors:  Lizette Visser; Marie-José Melief; Debby van Riel; Marjan van Meurs; Ella A Sick; Seiichi Inamura; Jeffrey J Bajramovic; Sandra Amor; Rogier Q Hintzen; Leonie A Boven; Bert A 't Hart; Jon D Laman
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

2.  Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.

Authors:  Bart O Roep; Nanette Solvason; Peter A Gottlieb; Joana R F Abreu; Leonard C Harrison; George S Eisenbarth; Liping Yu; Michael Leviten; William A Hagopian; John B Buse; Matthias von Herrath; Joanne Quan; Robert S King; William H Robinson; Paul J Utz; Hideki Garren; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2013-06-26       Impact factor: 17.956

3.  Building immune tolerance through DNA vaccination.

Authors:  Robin J Parks; Emanuela Gussoni
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-06       Impact factor: 11.205

Review 4.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

Review 5.  Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.

Authors:  Lawrence Steinman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 6.  Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.

Authors:  Peter Gottlieb; Paul J Utz; William Robinson; Lawrence Steinman
Journal:  Clin Immunol       Date:  2013-09-01       Impact factor: 3.969

7.  Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Authors:  Lisa H Tostanoski; Yu-Chieh Chiu; James I Andorko; Ming Guo; Xiangbin Zeng; Peipei Zhang; Walter Royal; Christopher M Jewell
Journal:  ACS Nano       Date:  2016-09-07       Impact factor: 15.881

8.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 10.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.